Membership

Quality Global Supply Australia Pty Ltd (QGS) is a research, development and manufacturing facility specializing in plant and herb extracts based in the Tuggerah region of New South Wales, Australia. QGS, in conjunction with a number of Australian Universities and Research Institutes, has worked together to become the first in the world to extract QV0 from the Manuka plant (Leptospermum). QV0, which attacks only cancer cells without harming healthy cells, offers a new solution to the plague of cancer.

QGS has joined forces with Australian research institutes to complete cell and animal experiments on QV0's cancer cell inhibition and tumor efficacy. The results, which have been published in international oncology journals, show that the use of QV0 greatly inhibited tumor growth without any negative effects on normal cells or animal health. This success has attracted the attention of many organizations specializing in cancer treatment, and the research institute has received full support from Australian government agencies. Phase I human clinical trials are being conducted independently at research and development facilities and hospitals in Sydney, and are fully funded by the relevant Australian agencies.

While promoting QV0 as a medicine, in order to help those who are suffering from cancer as soon as possible, QGS utilizes QV0 as one of the raw materials, selects all-natural ingredients under the guidance of Australian scientists, and produces the "Defender" solid drink through scientific formulation. The drink contains a large number of natural polyphenols and antioxidants that are beneficial to human health.

Over the past two years since Defender was introduced to the market, the company has received a great deal of positive feedback from users who have provided a wide variety of therapeutic feedback, some of which exceeded the expectations of QV0's researchers, especially in terms of the speed with which the effects are produced in the body, while in contrast, the negative feedback has been minimal, and has exceeded the expectations of those who have designed Defender as a solid beverage. As a result, QGS decided to accelerate the development of QV0 as an oncology drug and developed a R&D program from solid beverage to nutraceutical and ultimately to drug and chose an Australian focused R&D strategy with international collaborations.

QGS is a start-up company that can't afford to invest heavily in R&D and sell below cost at the same time, so it wants to help people while getting feedback on how it's being used to guide QV0's medical research. To this end, QGS is willing to sell the Defender product line to its members at below-cost while building a limited number of Defender members accordingly. These guidelines and protocols are hereby established.